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Abstract 
Castleman's disease are referred to a group of rare 
disorders that were discovered by Benjamin 
Castleman in 1954.   The disease is more common in 
HIV positive patients and has been linked to human 
herpesvirus 8.  The disease is diagnosed with 
excisional lymph node biopsy and carries a good 
prognosis.  Treatment options including radiation, 
rituximab based therapy or monitoring. 
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Disease 
This disease was reported by Benjamin Castleman in 
1954 (Castleman B, Towne V). Castleman disease is 
a heterogeneous cluster of disorders, with distinct 
unicentric CD (UCD) and multicentric CD (MCD) 
subtypes. Unicentric Castleman disease (UCD) is 
localized and carries an excellent prognosis, whereas 
multicentric Castleman disease (MCD) is a systemic 
disease occurring most commonly in the setting of 
HIV infection and is associated with human 
herpesvirus 8 and interleukin-6 (IL-6) in a 
significant proportion of cases. 
Phenotype/cell stem origin 
The disease appears to be polyclonal in origin in the 
majority of cases, however evidence for clonal 
expansion was documented in some cases, possibly 
representing transformation into non Hodgkin's 
lymphoma. In approximately 1/3 of the cases studied 
a monoclonal IgH rearrangement was documented. 
A minor T-cell clone, mostly in a polyclonal 
background, was also documented in some cases. 
Etiology 
The pathogenesis of Castleman disease is not fully 
understood; however, the central roles of interleukin 
(IL) 6 in UCD and both IL-6 and human herpesvirus 
(HHV) 8 in MCD have been well described. 
Epidemiology 
The epidemiology of CD is difficult to characterize 
accurately due to its rarity and clinical heterogeneity. 
The incidence of CD is estimated at 21-25 cases per 
million person-years, with 23% of those cases 
potentially representing MCD (Munshi N et 
al.,2015).  
The median age at presentation for UCD is 30-34 
years. For HIV-negative MCD is 49-66 years and 
HIV-positive MCD between 36-40 years. The sex 
distribution is approximately equal, though some 
series have reported a male predominance, generally 
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in the HIV-positive population. UCD also has a 
slight female predominance (1.4:1) (Talat N, et al., 
2011; Dispenzieri A et al., 2012). 
Clinics 
UCD may be asymptomatic at diagnosis and be 
incidentally discovered on chest or abdominal 
imaging performed for other reasons. Patients may 
present with painless lymphadenopathy or local 
anatomical symptoms varying by location. Common 
sites of presentation include the chest (30%), neck 
(23%), abdomen (20%), retroperitoneum (17%), 
and, rarely, the axilla (5%), groin (3%), or pelvis 
(2%). Intrathoracic disease is frequently found along 
the tracheobronchial tree or lung hila. Thoracic 
disease may present with cough, hemoptysis, 
dyspnea, or chest discomfort. Abdominal, 
retroperitoneal, and pelvic disease may present with 
abdominal or back discomfort. Disease confined to 
the peripheral lymph node chains, including the 
neck, axilla, or groin, may present with nontender 
lymphadenopathy.  
 
Systemic symptoms are a common feature of MCD; 
these include traditional "B" symptoms such as 
fever, night sweats, and weight loss, as well as 
lymphadenopathy and hepatosplenomegaly. More 
severe disease phenotypes include a severe, 
inflammatory vascular leak syndrome where patients 
may develop ascites, pericardial effusions, pleural 
effusions, and/or peripheral edema. Hematological 
sings include anemia driven by IL-6 or secondary to 
autoimmune hemolysis, immune thrombocytopenia, 
and acquired factor VIII deficiency (Marsh JH et al., 
1990; Marietta M  et al., 2003). Bronchiolitis 
obliterans, glomerulonephritis, and pemphigus have 
also been reported, with the presence of pemphigus 
associated with an unfavorable prognosis (Dong Y et 
al., 2015) MCD may be seen in association with the 
POEMS syndrome, which comprises 
polyneuropathy, organomegaly, endocrinopathy, 
monoclonal protein, and skin changes (Dispenzieri 
A et al., 2003).  
 
 Diagnosis A high index of suspicion is required in 
patients presenting with a compatible clinical 
picture, such as unifocal or generalized 
lymphadenopathy, splenomegaly, and/or 
unexplained constitutional symptoms (Chan K et al., 
2016). Common laboratory findings include anemia, 
thrombocytopenia, hypoalbuminemia, polyclonal 
hypergammaglobulinemia, and elevation of acute 
phase reactants, such as CRP. Elevations in 
circulating cytokines such as IL-6 and VEGF may 
also be detected although not essential for diagnosis, 
plasma VEGF levels can be useful in distinguishing 
and monitoring cases of CD associated with POEMS 
syndrome. Although not essential for diagnosis, 
plasma VEGF levels can be useful in distinguishing 
and monitoring cases of CD associated with POEMS 
syndrome. 
Pathology 
Castleman disease is a pathological diagnosis made 
by excisional biopsy of affected lymph node tissue. 
There are two variants: the hyaline-vascular and the 
plasma cell subtype. Most cases of UCD are 
histologically classified as the hyaline-vascular 
variant, which is characterized by increased numbers 
of small, hyalinized blood vessels within and 
between follicles with obliteration of the medullary 
sinuses (Soumerai J et al., 2014).  
 
The hyaline-vascular type show greater retention of 
the nodal architecture with hyperplastic follicles of 
varying sizes and focally patent medullary sinuses. 
The interfollicular region may be mildly 
hypervascular and characteristically contains sheets 
of mature-appearing plasma cells. Patients with 
"multicentric" Castleman disease show histologic 
features consistent with the plasma cell subtype. 
Treatment 
The optimal therapy for UCD is surgical excision if 
the mass is localized. For disease that cannot be 
completely excised, radiation therapy is an option 
due to its high rates of objective response, including 
complete responses in nearly one-half of reported 
cases (Bower M, et al., 2011).  
 
Available treatments for the MCD variant include 
glucocorticoids, single-agent and combination 
chemotherapy, antiviral strategies, and monoclonal 
antibody therapies targeting CD20 or IL-6.  
 
All patients with HIV infection and MCD should be 
initiated on combination antiretroviral therapy if 
they are not already taking it, although antiretroviral 
therapy alone is unlikely to independently result in a 
Castleman disease response. For initial systemic 
therapy, rituximab monotherapy has been 
recommended based on encouraging efficacy and 
safety results. Novel agents targeting interleukin 6 
(Siltuximab and tocilizumab) represent exciting new 
additions to the treatment armamenatrium (Casper C 
et al., 2013). Combination chemotherapy utilized for 
lymphoma must be reserved to relapsed or refractory 
disease (Bower M, 2012). 
Prognosis 
The prognosis of CD is variable and depends 
predominantly on disease subtype. As previously 
mentioned, patients with UCD enjoy excellent long-
term outcomes if complete resection can be 
achieved, with 10-year overall survival rates greater 
than 95%. 
 
Even in unresectable UCD cases, radiotherapy may 
offer good long-term response rates. %. 
 
The HIV- and HHV-8-associated subtype of MCD 
has the worst prognosis, with the majority of patients 
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in early studies dying within 2 years of diagnosis. 
Those patients with multicentric disease who fail to 
respond to steroid treatment have a serious disease. 
Cytogenetics 
Cytogenetics morphological 
Many of the cases so far studied showed a normal 
karyotyope. Occasional abnormalities were found in 
a few patients, but none known to be a "driver" 
chromosome abnormality. There is growing 
evidence suggesting that the clonal proliferation 
involved dysplastic stromal cells (Chang et al., 
2014). 
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